U.S. Markets closed

Novogen Limited (NVGN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
3.280.00 (0.00%)
At close: 12:08PM EDT
People also watch
NYMXPRANPBMDGENEMEIP
Full screen
Previous Close3.28
Open3.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range3.28 - 3.50
52 Week Range0.70 - 3.82
Volume27
Avg. Volume23,632
Market Cap16.6M
Beta1.05
PE Ratio (TTM)-5.96
EPS (TTM)-0.55
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.77
Trade prices are not sourced from all markets
  • PR Newswire6 days ago

    Board Review of Business Operations and Governance

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appointment of Iain Ross as Chairman on 8 June 2017, and has involved an extensive process of consultation with shareholders and investors.

  • PR Newswire6 days ago

    Board Review of Business Operations and Governance

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appointment of Iain Ross as Chairman on 8 June 2017, and has involved an extensive process of consultation with shareholders and investors.

  • PR Newswire13 days ago

    Progress Update on Cantrixil(TM) (TRXE-002-1) Development

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage development candidate, Cantrixil (TRXE-002-1). Novogen commenced a phase I clinical trial of Cantrixil in ovarian cancer in December 2016.